Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza virus strain H5N1 clade 1 vaccine - sanofi pasteur

Drug Profile

Influenza virus strain H5N1 clade 1 vaccine - sanofi pasteur

Alternative Names: AF 03; Avian influenza (bird flu) virus vaccine - sanofi pasteur/NIAID; Emerflu; H5N1 influenza vaccine - sanofi pasteur; H5N1 split antigen influenza vaccine Alum adjuvanted - sanofi pasteur; Low-dose H5N1 vaccine - sanofi pasteur; Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) A/Vietnam/1194/2004 (NIBRG-14) - sanofi pasteur; Pandemic influenza vaccine - sanofi pasteur

Latest Information Update: 29 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi Pasteur
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Influenza A virus H5N1 subtype

Most Recent Events

  • 29 Nov 2017 Sanofi Pasteur's influenza virus strain H5N1 clade 1 vaccine is registered in USA and Australia and will not be sold commercially
  • 20 Mar 2015 The vaccine is approved in USA and Australia for Influenza A virus H5n1 subtype (Prevention)
  • 20 Mar 2015 No recent reports on development identified - Phase-II for Influenza-A virus H5N1 subtype (In children, Prevention) in Thailand (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top